

*Advancing therapies for patients resistant to current treatments*

## Company Overview:

- A clinical-stage company advancing **multi-modality oncology therapies**
- **Leadership team with proven track record** in oncology drug development and commercialization (e.g., ONIVYDE®), including successful IPO (e.g., PharmaEngine)
- International footprint across **Europe (France, Switzerland) and Taiwan** (global headquarters)
- Raised **CHF 75.5M (> USD 90M) to date**; Series B financing ongoing, preparing for IPO in 2027

## Our Team:



**Dr C. Grace Yeh**  
Chairperson & CEO

*Biotech entrepreneur and company builder*



**Dr Alain Herrera**  
Chief Medical Officer


*Oncology clinical development expert*



**Dr Armand de Gramont**  
President of R&D

*Oncology R&D expert*

# CORPORATE STRUCTURE AND PARTNERSHIPS




To support its planned IPO in Taiwan, Onward has restructured with a new Taiwan headquarters in Q4 2025.

Multiple assets:

1. Biomunex (OT-A201): through a global license agreement and equity investment
2. Emercell (OT-C001): acquired via equity investment
3. ICM (OT-S00X): through worldwide license
4. OT-A30X: internal discovery


# A DIFFERENTIATED PIPELINE ADDRESSING CANCER RESISTANCE

## Our multi-modality pipeline:




**OT-A201** is a first-in-class bispecific antibody targeting novel resistance mechanisms

- Solid tumor: Phase 1b initiated (2026H1)
- Hematology: Phase 1b planned (2026H2)




**OT-C001** is an off-the-shelf NK cell therapy in combination with antibodies

- Phase 1 ongoing (to be completed in 2026Q4)



**OT-S00X** is a novel small molecule to overcome tumor resistance by targeting cancer metabolism

- Lead optimization (candidate to be selected in 2026)



**OT-A30X** is a first-in-class multi-specific program with the flexibility to expand into bispecific, tri-specific, and ADC modalities

- Discovery stage

## Traction / Milestones:



### Phase 1a

- Favorable safety profile
- Early signals in unselected heavily-treated patients
- Combination potential

(OT-A201 and OT-C001)



### High Unmet Needs

Broad patient population with **> 30% relapse and refractory** rates in advanced cancers



### Strong partnering potential

- OT-A201: **US\$1B+** potential (comparable transactions)
- OT-C001: **Versatile platform** for combination with antibodies

# CONTACT INFORMATION



## Website:

[www.onward-therapeutics.com](http://www.onward-therapeutics.com)



## Contact us:

[info@onward-therapeutics.com](mailto:info@onward-therapeutics.com)



## Onward Therapeutics, Inc. (昂沃生物科技)

2F, No. 60, Songjiang Road, Taipei, Taiwan 104090

## Onward Therapeutics SA

Biopôle, bâtiment Sérine, Route de la Corniche 8, 1066  
Epalinges, Switzerland

## Onward Therapeutics France SAS

28 bis Rue de Richelieu, 75001 Paris, France



***“Together we can accomplish the extraordinary!”***